{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:56:34Z","timestamp":1771023394518,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,5,10]],"date-time":"2011-05-10T00:00:00Z","timestamp":1304985600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s10147-011-0243-1","type":"journal-article","created":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T09:51:33Z","timestamp":1304934693000},"page":"666-670","source":"Crossref","is-referenced-by-count":7,"title":["A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma"],"prefix":"10.1007","volume":"16","author":[{"given":"Jori S.","family":"Carter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Levi S.","family":"Downs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,10]]},"reference":[{"key":"243_CR1","unstructured":"American Cancer Society (2010) Cancer facts and figures. Available via ACS http:\/\/www.cancer.org\/acs\/groups\/content\/@nho\/documents\/document\/acspc-024113.pdf . Accessed August 2010"},{"key":"243_CR2","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.1996.14.6.1895","volume":"14","author":"MA Bookman","year":"1996","unstructured":"Bookman MA, McGuire MP III, Kilpatrick D et al (1996) Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 14:1895\u20131902","journal-title":"J Clin Oncol"},{"key":"243_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/cncr.23164","volume":"112","author":"LS Downs","year":"2008","unstructured":"Downs LS, Judson PL, Argenta PA et al (2008) A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer (Phila) 112:331\u2013339","journal-title":"Cancer (Phila)"},{"issue":"18 suppl","key":"243_CR4","doi-asserted-by":"crossref","first-page":"13038","DOI":"10.1200\/jco.2006.24.18_suppl.13038","volume":"24","author":"TM Tohnya","year":"2006","unstructured":"Tohnya TM, Gulley J, Arlene P et al (2006) Phase I study of lenalidomide, a novel thalidomide analog, in patients with refractory metastatic cancer. J Clin Oncol 24(18 suppl):13038 (abstract)","journal-title":"J Clin Oncol"},{"key":"243_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10637-008-9137-0","volume":"26","author":"SL Sanborn","year":"2008","unstructured":"Sanborn SL, Cooney MM, Dowlati A et al (2008) Phase I trial of docetaxel and thalidomide: a regimen based on metronomic principles. Invest New Drugs 26:355\u2013362","journal-title":"Invest New Drugs"},{"key":"243_CR6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1006\/gyno.1997.4787","volume":"66","author":"EM Swisher","year":"1997","unstructured":"Swisher EM, Mutch DG, Rader JS et al (1997) Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 66:480\u2013486","journal-title":"Gynecol Oncol"},{"key":"243_CR7","unstructured":"Aravantinos G, Zafiropoulos A, Bafaloukos D et al (1998) Topotecan in heavily pretreated platinum resistant ovarian cancer patients. 10th Symposium of New Drugs in Cancer Therapy, Amsterdam: 67"},{"key":"243_CR8","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1365-2141.2008.07372.x","volume":"143","author":"WW Li","year":"2008","unstructured":"Li WW, Hutnik M, Gehr G et al (2008) Antiangiogenesis in haematological malignancies. Br J Haematol 143:622\u2013631","journal-title":"Br J Haematol"},{"key":"243_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","volume":"69","author":"K Dredge","year":"2005","unstructured":"Dredge K, Horsfall R, Robinson SP et al (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69:56\u201363","journal-title":"Microvasc Res"},{"key":"243_CR10","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3324\/haematol.2009.005835","volume":"94","author":"G Aue","year":"2009","unstructured":"Aue G, Njuguna N, Tian X et al (2009) Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 94:1266\u20131273","journal-title":"Haematologica"},{"key":"243_CR11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","volume":"163","author":"LG Corral","year":"1999","unstructured":"Corral LG, Haslett PA, Muller GW et al (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163:380\u2013386","journal-title":"J Immunol"},{"key":"243_CR12","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1124\/jpet.102.048496","volume":"305","author":"PH Schafer","year":"2003","unstructured":"Schafer PH, Gandhi AK, Loveland MA et al (2003) Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 305:1222\u20131232","journal-title":"J Pharmacol Exp Ther"},{"key":"243_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood.V98.1.210","volume":"98","author":"FE Davies","year":"2001","unstructured":"Davies FE, Raje N, Hideshima T et al (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210\u2013216","journal-title":"Blood"},{"key":"243_CR14","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","volume":"96","author":"T Hideshima","year":"2000","unstructured":"Hideshima T, Chauhan D, Shima Y et al (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943\u20132950","journal-title":"Blood"},{"issue":"suppl 5","key":"243_CR15","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1053\/j.seminoncol.2005.06.018","volume":"32","author":"R Knight","year":"2005","unstructured":"Knight R (2005) IMiDs: a novel class of immunomodulators. Semin Oncol 32(suppl 5):S24\u2013S30","journal-title":"Semin Oncol"},{"issue":"suppl 1","key":"243_CR16","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/S0268-960X(10)70005-9","volume":"24","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Terpos E (2010) Lenalidomide: an update on evidence from clinical trials. Blood Rev 24(suppl 1):S21\u2013S26","journal-title":"Blood Rev"},{"key":"243_CR17","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","volume":"57","author":"D Zhu","year":"2008","unstructured":"Zhu D, Corral LG, Fleming YW et al (2008) Immunomodultory drugs revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 57:1849\u20131859","journal-title":"Cancer Immunol Immunother"},{"key":"243_CR18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ygyno.2010.02.022","volume":"117","author":"SM Temkin","year":"2010","unstructured":"Temkin SM, Yamada SD, Fleming GF et al (2010) A phase I study of temsirolimus and topotecan in the treatment of advanced and\/or recurrent gynecologic malignancies. Gynecol Oncol 117:473\u2013476","journal-title":"Gynecol Oncol"},{"key":"243_CR19","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1182\/blood-2009-08-239046","volume":"115","author":"F Gay","year":"2010","unstructured":"Gay F, Hayman SR, Lacy MQ et al (2010) Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 115:1343\u20131350","journal-title":"Blood"},{"key":"243_CR20","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2008-12-196238","volume":"114","author":"P Richardson","year":"2009","unstructured":"Richardson P, Jagannath S, Hussein M et al (2009) Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 114:772\u2013778","journal-title":"Blood"},{"key":"243_CR21","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312\u20133322","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-011-0243-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-011-0243-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-011-0243-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-011-0243-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T16:15:11Z","timestamp":1712420111000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-011-0243-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,10]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["243"],"URL":"https:\/\/doi.org\/10.1007\/s10147-011-0243-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,10]]}}}